Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 11/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.51 |
| ▸ | ILK | Q13418 | 1/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025480 | 0.74 | RAB9A (1.00) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL31712299 | 0.74 | RAB9A (0.55) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL827403 | 0.73 | RAB9A (0.67) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL19380001 | 0.72 | APP (0.70) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL12713530 | 0.72 | RAB9A (0.58) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| Hydrogen Sulfide SCHEMBL16859912 | 0.71 | RAB9A (0.64) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL21779833 | 0.71 | KDM4E (0.63) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL25165795 | 0.71 | RAB9A (0.53) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL2222770 | 0.70 | ILK (0.60) | RAB9AKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL6657577 | 0.69 | CYP2A6 (0.67) | KDM4EALDH1A1MAPTSMN1; SMN2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360111-A1 | COMPOSITIONS OF AGPAT4 INHIBITORS AND METHODS OF USING THEREOF TO TREAT CANCER | UNIV HONG KONG (CN) | 2025-11-27 | — | — | US | disclosed |
| EP-4640682-A2 | COMPOSITIONS OF AGPAT4 INHIBITORS AND METHODS OF USING THEREOF TO TREAT CANCER | The University Of Hong Kong (CN) | 2025-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360111-A1 | COMPOSITIONS OF AGPAT4 INHIBITORS AND METHODS OF USING THEREOF TO TREAT CANCER | AGPAT2, PLAAT4, ACAT2 | RAB9A 4180/4885KDM4E 1197/4885ALDH1A1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.